A critical assessment of edaravone acute ischemic stroke efficacy trials: Is edaravone an effective neuroprotective therapy?

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 10, 2010, Pages 1753-1763

  Lapchak, Paul A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Acute ischemic stroke; Antioxidant; Behavior; Clinical; Embolism; Neuroprotection; Radicut; Thrombolytic; Toxicity; Translational science

Indexed keywords

ALTEPLASE; NORPHENAZONE; OZAGREL; UROKINASE;

ACUTE KIDNEY FAILURE; ACUTE LUNG INJURY; AMPOULE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART ARREST; HEPATITIS; HUMAN; LIVER FUNCTION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NAUSEA; NEPHROTOXICITY; NEUROPROTECTION; NONHUMAN; PNEUMONIA; PRURITUS; RATING SCALE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; STROKE PATIENT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANIMALS; ANTIPYRINE; BRAIN ISCHEMIA; DRUG EVALUATION, PRECLINICAL; FREE RADICAL SCAVENGERS; HUMANS; NEUROPROTECTIVE AGENTS; STROKE; TRANSLATIONAL RESEARCH;

EID: 77953648503     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.493558     Document Type: Review

References (88)

1. Ingall T. Stroke: incidence, mortality, morbidity and risk. J Insur Med 2004;36(2):143-152
2. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119(3):480-486
3. The Internet Stroke Center: stroke statistics. Available from: http://www.strokecenter.org/patients/stats.htm. [Last accessed 17 May 2010]
4. Petty GW, Brown RD Jr, Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000;31(5):1062-1068
5. Petty GW, Brown RD Jr, Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 1999;30(12):2513-2516
6. Lapchak PA. Development of thrombolytic therapy for stroke: a perspective. Expert Opin Investig Drugs 2002;11(11):1623-1632
7. Schellinger PD, Fiebach JB, Mohr A, et al. Thrombolytic therapy for ischemic stroke: review. Part II: tra- arterial thrombolysis, vertebrobasilar stroke, phase IV trials, and stroke imaging. Crit Care Med 2001;29(9):1819-1825
8. Schellinger PD, Fiebach JB, Mohr A, et al. Thrombolytic therapy for ischemic stroke: a review. Part I: Intravenous thrombolysis. Crit Care Med 2001;29(9):1812-1818
9. Verstraete M. Newer thrombolytic agents. Ann Acad Med Singapore 1999;28(3):424-433
10. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359(13):1317-1329 .. Extremely important study showing that alteplase could be used within 4.5 h of a stroke.
11. Bluhmki E, Chamorro A, Davalos A, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol 2009;8(12):1095-1102
12. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333(24):1581-1587
13. Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res 2010;1(2):96-107
14. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22(9):391-397
15. Lapchak PA, Araujo DM. Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs 2007;12(1):97-112
16. Facchinetti F, Dawson VL, Dawson TM. Free radicals as mediators of neuronal injury. Cell Mol Neurobiol 1998;18(6):667-682
17. Love S. Oxidative stress in brain ischemia. Brain Pathol 1999;9(1):119-131
18. Watanabe T, Tahara M, Todo S. The novel antioxidant edaravone: from bench to bedside. Cardiovasc Ther 2008;26(2):101-114
19. Yoshida H, Yanai H, Namiki Y, et al. Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev 2006;12(1):9-20
20. Floyd RA. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 1999;222(3):236-245
21. Nakashima M, Niwa M, Iwai T, Uematsu T. Involvement of free radicals in cerebral vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat. Free Radic Biol Med 1999;26(5-6):722-729
22. Cherubini A, Ruggiero C, Polidori MC, Mecocci P. Potential markers of oxidative stress in stroke. Free Radic Biol Med 2005;39(7):841-852
23. Lapchak PA, Araujo DM. Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke. CNS Drug Rev 2003;9(3):253-262
24. Siesjo BK, Katsura K, Zhao Q, et al. Mechanisms of secondary brain damage in global and focal ischemia: a speculative synthesis. J Neurotrauma 1995;12(5):943-956
25. Siesjo BK, Siesjo P. Mechanisms of secondary brain injury. Eur J Anaesthesiol 1996;13(3):247-268
26. Lee BJ, Egi Y, van Leyen K, et al. Edaravone, a free radical scavenger, protects components of the neurovascular unit against oxidative stress in vitro. Brain Res 2010;1307:22-27
27. Higashi Y. Edaravone for the treatment of acute cerebral infarction: role of endothelium-derived nitric oxide and oxidative stress. Expert Opin Pharmacother 2009;10(2):323-331
28. Kono H, Woods CG, Maki A, et al. Electron spin resonance and spin trapping technique provide direct evidence that edaravone prevents acute ischemia-reperfusion injury of the liver by limiting free radical-mediated tissue damage. Free Radic Res 2006;40(6):579-588
29. Banno M, Mizuno T, Kato H, et al. The radical scavenger edaravone prevents oxidative neurotoxicity induced by peroxynitrite and activated microglia. Neuropharmacology 2005;48(2):283-290
30. Shichinohe H, Kuroda S, Yasuda H, et al. Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia. Brain Res 2004;1029(2):200-206
31. Higashi Y, Jitsuiki D, Chayama K, Yoshizumi M. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases. Recent Patents Cardiovasc Drug Discov 2006;1(1):85-93
32. Yoshida H, Sasaki K, Namiki Y, et al. Edaravone, a novel radical scavenger, inhibits oxidative modification of low-density lipoprotein (LDL) and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase. Atherosclerosis 2005;179(1):97-102
33. Amemiya S, Kamiya T, Nito C, et al. Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. Eur J Pharmacol 2005;516(2):125-130
34. Xiao B, Bi FF, Hu YQ, et al. Edaravone neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats. Neurotox Res 2007;12(3):155-162
35. Kikuchi K, Kawahara K, Tancharoen S, et al. The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. J Pharmacol Exp Ther 2009;329(3):865-874
36. Zhang N, Komine-Kobayashi M, Tanaka R, et al. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 2005;36(10):2220-2225
37. Ishikawa A, Yoshida H, Metoki N, et al. Edaravone inhibits the expression of vascular endothelial growth factor in human astrocytes exposed to hypoxia. Neurosci Res 2007;59(4):406-412 (Pubitemid 350011198)
38. Kikuchi K, Tancharoen S, Matsuda F, et al. Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4. Biochem Biophys Res Commun 2009;390(4):1121-1125
39. Nakamura T, Kuroda Y, Yamashita S, et al. Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. Stroke 2008;39(2):463-469
40. Yagi K, Kitazato KT, Uno M, et al. Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke 2009;40(2):626-631
41. Kano T, Harada T, Katayama Y. Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model. Neurol Res 2005;27(5):499-502 (Pubitemid 41040836)
42. Oishi R, Itoh Y, Nishibori M, et al. Effect of MCI-186 on ischemia-induced changes in monoamine metabolism in rat brain. Stroke 1989;20(11):1557-1564
43. Nishi H, Watanabe T, Sakurai H, et al. Effect of MCI-186 on brain edema in rats. Stroke 1989;20(9):1236-1240
44. Jin YJ, Mima T, Raicu V, et al. Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. Neurosci Res 2002;43(1):75-79
45. Nito C, Kamiya T, Amemiya S, et al. The neuroprotective effect of a free radical scavenger and mild hypothermia following transient focal ischemia in rats. Acta Neurochir Suppl 2003;86:199-203
46. Watanabe T, Yuki S, Egawa M, Nishi H. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 1994;268(3):1597-1604
47. Wu TW, Zeng LH, Wu J, Fung KP. MCI-186: further histochemical and biochemical evidence of neuroprotection. Life Sci 2000;67(19):2387-2392
48. Tanahashi N, Fukuuchi Y. Treatment of acute ischemic stroke: recent progress. Intern Med 2002;41(5):337-344
49. Wang CX, Shuaib A. Neuroprotective effects of free radical scavengers in stroke. Drugs Aging 2007;24(7):537-546
50. Kitagawa Y. Edaravone in acute ischemic stroke. Intern Med 2006;45(5):225-226
51. Abe K. Edaravone. Nippon Rinsho 2006;64(Suppl 7):548-553
52. STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30(12):2752-2758
53. Chehrazi BB, Seibert JA, Kissel P, et al. Evaluation of recombinant tissue plasminogen activator in embolic stroke. Neurosurgery 1989;24(3):355-360
54. Gross CE, Raymond SJ, Howard DB, Bednar MM. Delayed tissue-plasminogen activator therapy in a rabbit model of thromboembolic stroke. Neurosurgery 1995;36(6):1172-1177
55. Phillips DA, Davis MA, Fisher M. Selective embolization and clot dissolution with tPA in the internal carotid artery circulation of the rabbit. AJNR Am J Neuroradiol 1988;9(5):899-902
56. Phillips DA, Fisher M, Smith TW, Davis MA. The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model. Ann Neurol 1988;23(4):391-394
57. Zivin JA, Fisher M, DeGirolami U, et al. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985;230(4731):1289-1292
58. Lapchak PA, Araujo DM, Zivin JA. Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol 2004;185(1):154-159
59. Lapchak PA, Zivin JA. The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. Exp Neurol 2009;215(1):95-100
60. Lapchak PD, Maher P, Schubert D, Zivin JA. Baicalein, an antioxidant 12/15 lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes. Neuroscience 2007;150(3):585-591
61. Broderick JP, Lu M, Kothari R, et al. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke 2000;31(10):2335-2341
62. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke 2000;31(4):811-816
63. Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 1994;25(11):2220-2226. The first study to validate a stroke scale in patients treated with tPA.
64. Lyden P, Lu M, Jackson C, et al. Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators. Stroke 1999;30(11):2347-2354
65. Otomo E. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003;15(3):222-229
66. Otomo E. Late phase 2 clinical trial of MCI-186 on acute cerebral infarction: a dose-finding double-blind study. J Clin Exp Med 1998;185:841-863
67. Otomo E, Tohgi H, Kogure K, et al. Clinical efficacy of a free radical scavenger, MCI-186, on acute cerebral infarction: Early phase II clinical trial. Ther Res 1998;19:1311-1332
68. Inatomi Y, Takita T, Yonehara T, et al. Efficacy of edaravone in cardioembolic stroke. Intern Med 2006;45(5):253-257
69. Mishina M, Komaba Y, Kobayashi S, et al. Efficacy of edaravone, a free radical scavenger, for the treatment of acute lacunar infarction. Neurol Med Chir (Tokyo) 2005;45(7):344-8; discussion 8
70. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial (TOAST) Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24(1):35-41
71. Ohta Y, Takamatsu K, Fukushima T, et al. Efficacy of the free radical scavenger, edaravone, for motor palsy of acute lacunar infarction. Intern Med 2009;48(8):593-596
72. Shinohara Y, Saito I, Kobayashi S, Uchiyama S. Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). Cerebrovasc Dis 2009;27(5):485-492
73. Sinha MK, Anuradha HK, Juyal R, et al. Edaravone in acute ischemic stroke, an Indian experience. Neurol Asia 2009;14:7-10
74. Toyoda K, Fujii K, Kamouchi M, et al. Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. J Neurol Sci 2004;221(1-2):11-17
75. Hacke W, Schwab S, Horn M, et al. 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol 1996;53(4):309-315
76. Unno Y, Katayama M, Shimizu H. Does functional outcome in acute ischaemic stroke patients correlate with the amount of free-radical scavenger treatment?: a retrospective study of edaravone therapy. Clin Drug Investig 2010;30(3):143-155
77. Shibata H, Shigenori A, Izawa M, et al. Phase I clinical study of MCI-186 (Edaravone, 3-methyl-1-phenyl-2-pyrazolin-5-one) in healthy volunteers: safety and pharmacokinetics of single and multiple administrations. Jpn J Clin Pharmacol Ther 1998;29(6):863-876
78. TManalysis of CNB-001 a novel curcumin-based neurotrophic\ neuroprotective lead compound to treat stroke: comparison with NXY-059 and Radicut. Transl Stroke Res 2010; In press
79. Risk/benefit assessment of drugs analysis and response. Available from: http:// www.rad-ar.or.jp. [Last accessed 17 May 2010]
80. Hishida A. Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance. Clin Exp Nephrol 2007;11(4):292-296
81. Hishida A. Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone. Clin Exp Nephrol 2009;13(2):118-122
82. Abe M, Kaizu K, Matsumoto K. A case report of acute renal failure and fulminant hepatitis associated with edaravone administration in a cerebral infarction patient. Ther Apher Dial 2007;11(3):235-240
83. Mishina M, Komaba Y, Kobayashi S, et al. Administration of free radical scavenger edaravone associated with higher frequency of hemorrhagic transformation in patients with cardiogenic embolism. Neurol Med Chir (Tokyo) 2008;48(7):292-297
84. Yoshifumi T. Benefits of Pre-treatment with edaravone in tPA intravenous therapy for acute cerebral infarction. XXIII International Symposium on Cerebral Blood Flow [abstract]. J Cereb Blood Flow Metab 2007;(Suppl 1):BP34-06M
85. Safety and pharmacokinetics of MCI-186 in subjects with acute ischemic stroke. Available from: http:// www.clinicaltrials.gov/ct2/show/. [Last accessed 17 May 2010]
86. Kageyama M, Toriyama S, Tsuboshita A. A post-marketing drug use survey of a neuroprotective drug Radicut injection 30mg (nonproprietary name: edaravone) for acute ischmic stroke. J New Rem Clin 2009;58:1212-1226
87. Shuaib A, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357(6):562-571
88. Bath PM, Gray LJ, Bath AJ, et al. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol 2009;157(7):1157-1171